BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//DataCutoff//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:DataCutoff · $MRK.DE readouts
X-WR-CALDESC:Clinical-trial primary completion dates from ClinicalTrials.go
 v\, refreshed nightly by DataCutoff. Not investment advice.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT03815643-pcd@datacutoff.com
DTSTAMP:20261118T192902Z
DTSTART;VALUE=DATE:20261124
DTEND;VALUE=DATE:20261125
SUMMARY:Avelumab readout (P3) · EMD Serono Research & Development Institut
 e\, Inc. $MRK.DE
DESCRIPTION:Avelumab Program Rollover Study\n\nPrimary completion date: 202
 6-11-24 (estimated)\nOriginally planned: 2024-01-28 (+33.9 months)\nPhase 
 3 · Oncology · Solid Tumors\nEnrollment: 205 · Sites: 104\n\nPrimary co
 mpletion = last participant's primary-endpoint data collected\; topline re
 sults usually follow weeks to months later. Sponsor-reported\, often an es
 timate. Not investment advice.\n\nhttps://datacutoff.com/radar.html?nct=NC
 T03815643\nhttps://clinicaltrials.gov/study/NCT03815643
URL:https://datacutoff.com/radar.html?nct=NCT03815643
CATEGORIES:Oncology,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
